The FLT3 gene in humans encodes the protein FLT3, also known as Fms-like tyrosine kinase 3 (CD135). The class III receptor tyrosine kinase family includes FLT3, a cytokine receptor.FLT3 is the cytokine Flt3 ligand (FLT3L)'sreceptor. On the surface of many hematopoietic progenitor cells, FLT-3 is expressed. The normal development of hemopoietic stem cells and progenitor cells depends on FLT3 signaling. One of the genes with the highest frequency of mutations in acute myeloid leukemia (AML) is FLT3. Furthermore, high FLT3 levels in blast cells from some AML patients without FLT3 mutations have been observed. The prognosis may be worse when these levels are high. Cell proliferation, differentiation, and survival are influenced by FLT3 signaling. FLT3 is crucial for the growth of lymphocytes (B and T cells), but not for the growth of other blood cells. The cytokines TNF-Alpha and TGF-Beta both inhibit FLT3 activity.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V69488 | BPR1K871 (DBPR114) | 2443767-35-7 | BPR1K871 (DBPR114) is a potent and specific FLT3/AURKA dual (bifunctional) inhibitor (antagonist) with IC50s of 19 nM and 22 nM for FLT3 and AURKA respectively. |
|
V88051 | D-65476 | 249762-74-1 | D-65476 is a type III receptor tyrosine kinase (Flt3) inhibitor. |
|
V69292 | Dovitinib lactate (CHIR-258 lactate; TKI-258 lactate) | 692737-80-7 | Dovitinib lactate (TKI258 lactate) is a multi-target tyrosine kinase inhibitor, inhibiting FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β with IC50s of 1, 2, 8/9 respectively. |
|
V69283 | Dovitinib-d8 (Dovitinib d8) | 1246819-84-0 | Dovitinib-d8 is the deuterated form of Dovitinib. |
|
V102949 | Flonoltinib sulfate | 2568842-57-7 | Flunotinib maleate is an oral dual JAK2/FLT3 inhibitor with IC50 of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. |
|
V105277 | FLT3 Ligand-Linker Conjugate 1 | 2769753-49-1 | FLT3 ligand-adapter conjugate 1 contains the FLT3 ligand and a PROTAC adaptor that recruits the E3 ligase VHL. |
|
V69489 | FLT3-IN-10 | 2088735-51-5 | FLT3-IN-10 (compound 7c) is a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3). |
|
V69500 | FLT3-IN-18 | 752191-77-8 | FLT3-IN-18 is a potent and specific FLT3 inhibitor (antagonist) with IC50 of 0.003 μM. |
|
V69492 | FLT3-IN-19 | 2237234-48-7 | FLT3-IN-19 (Comp 50) is a potent and specific FLT3 inhibitor (antagonist) with IC50 of 0.213 nM. |
|
V85849 | FLT3-IN-24 | ||
|
V85815 | FLT3-IN-25 | ||
|
V93273 | FLT3-IN-27 | FLT3-IN-27 (Compound 49) is a FLT3-ITD inhibitor with IC50 of 174 nM. | |
|
V105152 | FLT3-IN-28 | FLT3-IN-28 (compound 12y) is an orally available FLT3 inhibitor with antitumor activity. | |
|
V69490 | FLT3-IN-6 | 2377141-31-4 | FLT3-IN-6 is a potent and specific inhibitor of FLT3-ITD (FLT3 mutant) with IC50 of 1.336 nM. |
|
V104484 | FLT3-ITD-IN-2 | FLT3-ITD-IN-2 (Compound A1) is an inhibitor of FLT3-ITD kinase with IC50 of 2.12 nM. | |
|
V88050 | FLT3/ITD-IN-5 | 3023632-62-1 | FLT3/ITD-IN-5 (Example 6) is an orally active FLT3 and FLT3-ITD inhibitor with IC50 values of 0.088 and 0.348 nM, respectively. |
|
V88048 | FLT3D835Y/F691L-IN-1 | FLT3D835Y/F691L-IN-1 (compd 8v) is an orally active inhibitor of the D835Y/F691L secondary mutations in the 3-tyrosine kinase domain of FLT3 (IC50 of 1.5 and 9.7 nM). | |
|
V105141 | FW-1 | FW-1 is a type I inhibitor of FLT3 with an IC50 of approximately 1 μM. | |
|
V2516 | HM43239 | 2569527-64-4 | HM-43239 is a novel,selectively and orally active small molecule inhibitor of FLT3. |
|
V69496 | HP1142 | 381173-58-6 | HP1142 is a potent and specific inhibitor of the FLT3 receptor tyrosine kinase (FLT3/ITD mutation). |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
